Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.

Cancer cell - 13 Jul 2010

Jeanne Marion, Lallemand-Breitenbach Valérie, Ferhi Omar, Koken Marcel, Le Bras Morgane, Duffort Stéphanie, Peres Laurent, Berthier Caroline, Soilihi Hassane, Raught Brian, de Thé Hugues

Abstract excerpt

As(2)O(3) cures acute promyelocytic leukemia (APL) by initiating PML/RARA oncoprotein degradation, through sumoylation of its PML moiety. However, how As(2)O(3) initiates PML sumoylation has remained largely unexplained. As(2)O(3) binds vicinal cysteines and increases reactive oxygen species (ROS...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Arsenic Trioxide
Share to Arsenicals
Share to Intranuclear Inclusion Bodies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Promyelocytic, Acute

Share to Oxides

Share to Promyelocytic Leukemia Protein

Share to Proteasome Inhibitors

Share to Small Ubiquitin-Related Modifier Proteins

Source

Identifiers

PMID: 20609355
DOI: 10.1016/j.ccr.2010.06.003

Genes

PML
RARA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20609355-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PML/RARA oxidation and arsenic binding initiate the antileukemia response of As2O3.PMID 20609355Read ↗

Acute promyelocytic leukemia, arsenic, and PML bodiesSemantic proximity Read ↗

Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation.Semantic proximity Read ↗

Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.Semantic proximity Read ↗

Requirement of PML SUMO interacting motif for RNF4- or arsenic trioxide-induced degradation of nuclear PML isoforms.Semantic proximity Read ↗

Arsenic-induced PML targeting onto nuclear bodies: Implications for the treatment of acute promyelocytic leukemiaSemantic proximity Read ↗

SUMO deconjugation is required for arsenic-triggered ubiquitylation of PML.Semantic proximity Read ↗

Molecular Targets of Arsenic Trioxide in Malignant CellsSemantic proximity Read ↗

PML mutants from arsenic-resistant patients reveal SUMO1-TOPORS and SUMO2/3-RNF4 degradation pathways.Semantic proximity Read ↗

Phenylarsine Oxide Can Induce the Arsenite-Resistance Mutant PML Protein Solubility Changes.Semantic proximity Read ↗

ZnO Q-Dots Nanoparticles: Intensifying ROS Stress to Improve Anticancer Drug EfficacySemantic proximity Read ↗

In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteinsSemantic proximity Read ↗

FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemiasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.